Merck & Co. (MRK) announced Sunday that preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab, its antibody therapy targeting PD-1, in patients with advanced melanoma, was presented at ASCO.
Merck gapped open higher Monday, but traded in a range for the majority of the day. The stock closed up by 1.75 at $48.45 on above average volume. Merck closed challenging the highs of the year, trading at over a 1-month high.
For comments and feedback: editorial@rttnews.com